HIV Treatment
Tibotec Applies for Traditional Approval of NNRTI Etravirine (Intelence)
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 10 February 2009 13:12
- Written by Tibotec
Tibotec announced on February 5, 2009 that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for traditional approval for its NNRTI etravirine (Intelence). The application includes 48-week data from 2 Phase 3 studies known as DUET-1 and DUET-2.
HIV Mutations Can both Reduce and Enhance Virological Response to Boosted Darunavir (Prezista)
- Details
- Category: Approved HIV Drugs
- Published on Friday, 30 January 2009 13:12
- Written by HIVandHepatitis.com
Development of viral resistance to anti-HIV drugs is a potential barrier to long-term treatment success. In the current study, published ahead of print in the January 15, 2009 online edition of the Journal of Antimicrobial Chemotherapy, French researchers sought to identify a pattern of HIV protease gene mutations associated with virological response to regimens containing ritonavir-boosted darunavir (Prezista).
Antiretroviral Treatment Interruption Is Associated with Evidence of Kidney Dysfunction in SMART Study
- Details
- Category: When to Start ART?
- Published on Tuesday, 27 January 2009 00:00
- Written by Liz Highleyman
Evidence continues to accumulate showing that antiretroviral treatment interruption, as evaluated in the large SMART trial, is a potentially risky strategy. A new study, published in the January 2, 2009 issue of AIDS, sheds further light on kidney dysfunction in this setting.
Changes in Darunavir (Prezista) Resistance Score after Previous Failure of Boosted Tipranavir (Aptivus) in Multidrug-resistant HIV Patients
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 27 January 2009 13:12
- Written by Ronald Baker
Darunavir (Prezista) and tipranavir (Aptivus) are the most recently-approved protease inhibitors. Boosted with low-dose ritonavir (Norvir), they both exhibit activity against multidrug-resistant strains of HIV. However, researchers have not yet clearly defined the optimal sequencing of these 2 antiretroviral agents when used in salvage regimens for highly treatment-experienced patients [1,2].
Adherence Is Reduced in Patients Who Don't Think They Need Antiretroviral Treatment
- Details
- Category: HIV Treatment
- Published on Friday, 23 January 2009 13:12
- Written by Liz Highleyman
Adherence is a key contributor to optimal response to antiretroviral therapy. Many factors influence good or poor adherence, including an individual's perceived need for treatment, according to a study published in the December 1, 2008 Journal of Acquired Immune Deficiency Syndromes.
More Articles...
- Gilead Plans Clinical Trial of 4-in-1 Antiretroviral Combination Pill Containing Experimental Integrase Inhibitor Elvitegravir
- A Review of HIV Monotherapy with Ritonavir-boosted Protease Inhibitors
- HIV9: More Data Demonstrate Similar Efficacy of Abacavir and Tenofovir
- Antiretroviral Therapy during Primary HIV Infection Offers Little Lasting Benefit
Web Design and Development by